SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.26+1.2%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (2653)1/25/2001 11:49:15 PM
From: Ian@SI  Read Replies (2) of 52153
 
Peter,

I passed on your comments / concerns to a Dr friend who reviewed them with some of the researchers.

Those researchers felt that the efficacy is VERY conservatively stated and that the morbidity / mortality benefits are quite clear and will prove to be exceedingly positive in ongoing trials.

He further advised that he believes that once we get beyond the need for macro enzyme parameters to define benefit, as long as the mortality data holds up, this will be a Fast Track drug with a large market. Remember, this is just 1 of 4 potential blockbusters that the company has in trials.

I trust his judgment completely when it comes to emerging biotechs.

Ian.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News